 Genetic Technologies Limited ASX: GTG; NASDAQ: GENE the Company, a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering of 3,500,000 American Depositary Shares ADSs, each representing six hundred 600 of the Companys ordinary shares, at an effective purchase price of 2.00 per ADS, and 500,000 pre-funded warrants, at an effective purchase price of 1.9999 per pre-funded warrant, for aggregate gross proceeds of approximately 8.0 million. The Company intends to use the net proceeds from this offering to support the introduction and distribution of our new products in the United States, for general product research and development, including the development of polygenic risk tests, and reimbursement studies with TGen in the United States, for implementation of our consumer initiated testing platform, preparation for potential COVID-19 testing, COVID-19 risk test for developing serious disease from contracting COVID-19, for working capital and new equipment purchases. 